ArticleCureus2025
A Case Report of Metastatic Melanoma in the Transverse Colon.
Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colonic metastasis from melanoma is extremely rare and is often asymptomatic, complicating detection. Diagnosis requires imaging and endoscopic evaluation. Treatment typically involves surgical resection with systemic therapies like immunotherapy and targeted therapy. However, immunotherapy has increased immune-related adverse events, including gastrointestinal perforation, a rare but serious complication. This report details a case of a Caucasian male patient in his 60s with a history of excised scalp melanoma eight years prior, who developed metastatic melanoma in the transverse colon. After initiating combination immunotherapy with ipilimumab/nivolumab, he suffered a bowel perforation, necessitating palliative care. The case underscores the need for vigilant monitoring for asymptomatic gastrointestinal tract metastases in melanoma patients and careful risk assessment when considering immunotherapy. It emphasizes the challenge of balancing aggressive treatment with managing potentially severe adverse events.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.